INFU · InfuSystem Holdings, Inc · Webcasts, Transcripts & Audio
$14.29
+0.23 (+1.60%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$281.67M
Shares
20.03M
Volume · Nov 20
101.02K
Avg daily vol (3M)
134.57K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
InfuSystem Holdings, Inc Webcasts
Earnings calls, investor updates, investor days and conferences for InfuSystem Holdings, Inc (INFU), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-03
InfuSystem Holdings, Inc (INFU) Q3 2026 Earnings Call Transcript
Confident tone
Oncology Performance
Wound Care and Compression Therapy
ERP Implementation and Collections
Revenue
$37.59M
▲ 3% YoY Diluted EPS
$0.15
▲ 36.4% YoY Gross margin
57.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Capital Markets Day
Investor event
2026-09-24
InfuSystem Holdings, Inc (INFU) September 24, 2026 Capital Markets Day
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-04
InfuSystem Holdings, Inc (INFU) Q2 2026 Earnings Call Transcript
Positive tone
Lymphedema business and CMS prior authorization
ERP system implementation benefits
Growth timeline and future aspirations
Revenue
$36.93M
▲ 2.6% YoY Diluted EPS
$0.15
▲ 25% YoY Gross margin
58.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
InfuSystem Holdings, Inc (INFU) Q1 2026 Earnings Call Transcript
Positive tone
Wound care growth
ERP system implementation
GE Healthcare contract restructuring
Revenue
$33.68M
▼ 3% YoY Diluted EPS
$0.05
Gross margin
58.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-24
InfuSystem Holdings, Inc (INFU) Q4 2025 Earnings Call Transcript
Confident tone
Q4 financial highlights
2026 financial outlook
Profitability and gross margin
Revenue
$36.23M*
▲ 7% YoY Gross margin
56.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
InfuSystem Holdings, Inc (INFU) Q3 2025 Earnings Call Transcript
Positive tone
Financial results and margin expansion
Wound Care growth and integration
Oncology business performance
Revenue
$36.49M
▲ 3.3% YoY Diluted EPS
$0.11
▲ 37.5% YoY Gross margin
57.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
InfuSystem Holdings, Inc (INFU) Q2 2025 Earnings Call Transcript
Positive tone
Margin expansion and profitability
Oncology business
ChemoMouthpiece reimbursement
Revenue
$36.00M
▲ 6.8% YoY Diluted EPS
$0.12
▲ 300% YoY Gross margin
55.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
InfuSystem Holdings, Inc (INFU) Q1 2025 Earnings Call Transcript
Confident tone
Q1 revenue and EBITDA growth
CEO succession and leadership transition
Segment performance (Patient Services and Device Solutions)
Revenue
$34.72M
▲ 8.5% YoY Diluted EPS
$-0.01
Gross margin
55.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-04
InfuSystem Holdings, Inc (INFU) Q4 2024 Earnings Call Transcript
Confident tone
Revenue Growth Across Business Lines
Wound Care Initiative Ramp-Up
2024 Accretion Year Results
Revenue
$33.85M*
▲ 6.5% YoY Gross margin
53.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
InfuSystem Holdings, Inc (INFU) Q3 2024 Earnings Call Transcript
Confident tone
Sanara / Chemo Mouthpiece joint venture
Device Solutions segment
Revenue growth and records
Revenue
$35.32M
▲ 10.7% YoY Diluted EPS
$0.08
▲ 166.7% YoY Gross margin
53.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
InfuSystem Holdings, Inc (INFU) Q2 2024 Earnings Call Transcript
Confident tone
Negative Pressure Wound Therapy expansion
NOPAIN Act and Pain Management
Oncology segment performance
Revenue
$33.70M
▲ 6.2% YoY Diluted EPS
$0.03
▲ 50% YoY Gross margin
49.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
InfuSystem Holdings, Inc (INFU) Q1 2024 Earnings Call Transcript
Confident tone
Strategic outlook and pipeline
Biomedical/Wound Care programs
Profitability and margin expansion
Revenue
$32.00M
▲ 5.4% YoY Diluted EPS
$-0.05
Gross margin
51.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-14
InfuSystem Holdings, Inc (INFU) Q4 2023 Earnings Call Transcript
Confident tone
GE Healthcare biomedical services contract
Wound Care and Sanara joint venture
Core oncology and pump rental business
Revenue
$31.77M*
▲ 10.2% YoY Gross margin
52.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
InfuSystem Holdings, Inc (INFU) Q3 2023 Earnings Call Transcript
Revenue
$31.91M
▲ 17% YoY Diluted EPS
$0.03
▲ 50% YoY Gross margin
48.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
InfuSystem Holdings, Inc (INFU) Q2 2023 Earnings Call Transcript
Revenue
$31.73M
▲ 17.4% YoY Diluted EPS
$0.02
Gross margin
49.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
InfuSystem Holdings, Inc (INFU) Q1 2023 Earnings Call Transcript
Revenue
$30.37M
▲ 13.5% YoY Diluted EPS
$-0.02
Gross margin
49.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-15
InfuSystem Holdings, Inc (INFU) Q4 2022 Earnings Call Transcript
Revenue
$28.83M*
▲ 8.7% YoY Gross margin
48.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
InfuSystem Holdings, Inc (INFU) Q3 2022 Earnings Call Transcript
Revenue
$27.28M
▲ 2.7% YoY Diluted EPS
$0.02
Gross margin
59.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Date not confirmed
InfuSystem Holdings, Inc (INFU) Q2 2022 Earnings Call Transcript
Revenue
$27.04M
▲ 8.9% YoY Diluted EPS
$-0.01
▼ 125% YoY Gross margin
55.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
InfuSystem Holdings, Inc (INFU) Q1 2022 Earnings Call Transcript
Revenue
$26.76M
▲ 9.4% YoY Diluted EPS
$-0.02
▼ 166.7% YoY Gross margin
57.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Date not confirmed
InfuSystem Holdings, Inc (INFU) Q4 2021 Earnings Call Transcript
Revenue
$26.52M*
▲ 7.3% YoY Gross margin
51.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-15
InfuSystem Holdings, Inc (INFU) Q3 2021 Earnings Call Transcript
Revenue
$26.57M
▲ 5.7% YoY Diluted EPS
$-0.02
▼ 114.3% YoY Gross margin
57.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
InfuSystem Holdings, Inc (INFU) Q2 2021 Earnings Call Transcript
Revenue
$24.83M
▼ 4.5% YoY Diluted EPS
$0.04
▼ 78.9% YoY Gross margin
60.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
InfuSystem Holdings, Inc (INFU) Q1 2021 Earnings Call Transcript
Revenue
$24.46M
▲ 13.5% YoY Diluted EPS
$0.03
Gross margin
59.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-17
InfuSystem Holdings, Inc (INFU) Q4 2020 Earnings Call Transcript
Revenue
$24.71M*
▲ 13.8% YoY Gross margin
60.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-12
InfuSystem Holdings, Inc (INFU) Q3 2020 Earnings Call Transcript
Revenue
$25.12M
▲ 16.9% YoY Diluted EPS
$0.14
▲ 180% YoY Gross margin
60.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-13
InfuSystem Holdings, Inc (INFU) Q2 2020 Earnings Call Transcript
Revenue
$26.00M
▲ 31.8% YoY Diluted EPS
$0.19
▲ 850% YoY Gross margin
61.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-14
InfuSystem Holdings, Inc (INFU) Q1 2020 Earnings Call Transcript
Revenue
$21.55M
▲ 18.5% YoY Diluted EPS
$-0.02
Gross margin
58.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-19
InfuSystem Holdings, Inc (INFU) Q4 2019 Earnings Call
Revenue
$21.71M*
▲ 23.6% YoY Gross margin
59.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–29 of 29 webcasts
Key facts
CIK
1337013
CUSIP
45685K102
13F (30d)
131 filings
116 filers
Visit website
Investor relations